(Hypertension. 1997;29:123.)
© 1997 American Heart Association, Inc.
Research Articles (Issue 1, Part 1) |
the Department of Physiology, Institute of Physiology/Pharmacology (A.W., P.F., G.G.), and Research Center for Endocrinology and Metabolism, Department of Internal Medicine (G.L.M., C.B., J.I.), University of Göteborg (Sweden); and Department of Pharmacology/Toxicology, Queens University, Kingston, Ontario, Canada (M.A.A.).
| Abstract |
|---|
|
|
|---|
Key Words: insulin-like growth factor I growth substances hypertension, renal fistula hemodynamics rats
| Introduction |
|---|
|
|
|---|
A complex interplay between hemodynamic factorssuch as transmural pressure, shear stress, flow, pulsatility, systolic wall stress, and circulating vasoactive substances, such as endothelin, Ang II, norepinephrine, and various growth factorsmay promote cardiovascular tissue growth.8 9 10 11 A number of studies have indicated an important role for IGF-I on cardiovascular development and tissue growth response.12 13 14 15 IGF-I acts both as a hormone and at the tissue level in an autocrine, paracrine, or intracrine manner.16 Furthermore, GH is the primary regulator of IGF-I synthesis and mRNA content.17 18 Some studies also suggest that tissue growth response depends on GH-R expression.19 20 21 Increased IGF-I expression, at both the mRNA and protein levels, is associated with the development of cardiovascular hypertrophy and hyperplasia during hemodynamic overload, ie, renal hypertension (2K1C), ACF, and aortic constriction, respectively,12 13 14 15 22 23 suggesting that the overexpression of IGF-I mRNA is mediated via an increased systolic wall stress. Whether a similar IGF-I and GH-R gene induction pattern, as occurs in cardiac tissue during hemodynamic challenge, also applies for vascular tissue has yet to be determined, although vascular smooth muscle cells have been shown to express increased IGF-I mRNA levels in relation to increased wall stress, as exemplified in an in vitro system24 and in vivo in obstructed urinary bladder and portal vein.25
Alterations in the circulation induced by experimental manipulations such as 2K1C and ACF promote structural adaptive responses, although the patterns of hemodynamic changes are widely different. An ACF results in a vigorous elevation of volume flow from the arterial to the venous side, leading to widening of the caval vein, which promotes a marked increase in vascular wall stress; or as demonstrated by Dobrin,26 increased circumferential stress initiates medial thickening. In contrast, the arterial system is unloaded with a reduction of afterload for the left ventricle, although the diastolic wall stress is increased. On the other hand, in the 2K1C model, arterial blood pressure increases slowly and persistently during the first 2 to 3 weeks after intervention.27 Comparison of these contrasting experimental models shows that the arterial circulation and left ventricle are less challenged in the early phase of the 2K1C hypertensive model, whereas the venous side and right ventricle receive an immediate and pronounced hemodynamic stimulus in the ACF model.
Currently, little is known about the in vivo involvement of components of the GH/IGF-I axis in vascular tissue during hemodynamic overload, especially with regard to great veins, an issue of particular relevance in bypass grafting surgery. The aim of the present study was to characterize the magnitude and time course of hemodynamic parameters and growth response processes involving the patterns of IGF-I and GH-R mRNA expressions in the caval vein and aorta in the 2K1C and ACF models, respectively. Moreover, the existence of IGF-I protein was visualized by means of immunohistochemistry in the volume-overloaded caval vein.
| Methods |
|---|
|
|
|---|
Aortocaval Fistula
Volume overload was induced during short-lasting anesthesia with barbiturate methohexital sodium (Brietal, Eli Lilly & Co; 75x10-3 g/kg body wt IP) in male normotensive Wistar rats weighing 160 to 200 g by means of a fistula between the aorta and inferior caval vein.28 The abdominal aorta was punctured with an 18-gauge disposable needle and advanced into the inferior caval vein. After the needle was withdrawn, the puncture site was sealed with cyanoacrylate glue. Before the abdomen was closed, the patency of the shunt was confirmed visually by mixing of arterial blood in the caval vein. A sham operation was performed in control rats by merely exposing the aorta and inferior caval vein.
Experiments were performed in ACF (n=8) and sham-operated (n=4) rats 4, 8, and 12 days postoperatively. The degree of shunting was moderate, without signs of cardiac failure, as demonstrated by no significant change in the ratio of liver wet weight to dry weight. To confirm the patency of the shunt, we checked for the presence of a systolic shunt murmur by auscultation. Only ACF rats showing decreased systolic pressure and clear-cut cardiac hypertrophy were included in the study. One rat at day 4, 2 rats at day 8, and 4 rats at day 12 were excluded per the above exclusion criteria.
Radiotelemetry
Radiotelemetric transducers (model TA11PA-C40, Data Sciences Inc) were implanted at least 2 weeks before ACF surgery in separate groups of male Wistar rats. The implantation was made into the abdominal aorta (n=5) or caval vein (n=5) through a midline laparotomy. The tip of the catheter faced upstream in the caval vein and downstream in the aorta, at least 1 cm below the renal artery. The catheter was held in place with a drop of cyanoacrylate glue. The transducer radio signals were collected by a receiver system (RA1010, Data Sciences) placed directly under the rat's cage, and the digital signal was transferred via a consolidation matrix (BCM100, Data Sciences) to a computer-based data-acquisition system (Dataquest IV, version 4, Data Sciences). Arterial and venous pressures were collected on-line at 150 Hz for 15 seconds at 10-minute intervals for each rat. Mean arterial and central venous pressures were monitored by the Dataquest IV software program and stored for later analysis. The shunt was created at the same level as the telemetry catheter tip in the caval vein and aorta, respectively. During the ACF operation, pressure monitoring was stopped for 2 hours.
2K1C Renal Hypertension
During short-lasting anesthesia as described above, 2K1C was induced in normotensive male Wistar rats weighing approximately 180 g by placement of a silver clip (0.18-mm diameter) around the left renal artery. The right kidney was left intact. A sham operation exposing the left renal artery was performed in control rats.
Experiments were performed on 2K1C (n=8) and sham-operated (n=4) rats 2, 4, and 7 days after surgery. Early systolic pressure elevation (
15% increase) was used as the inclusion criterion.27 Two rats at day 2, 3 rats at day 4, and 3 rats at day 7 were excluded from the study because of normotensive blood pressure.
Experimental Protocol
On the day of experimentation, rats were weighed and had their systolic pressure and heart rate measured by tail plethysmography (Narco BioSystems). After anesthesia, the heart, aorta, and caval vein were excised. The vessels were excised directly above the shunt toward the heart, with no tissue included from below the fistula. The vessels were trimmed of extra tissue and weighed before being snap-frozen in liquid nitrogen and stored at -80°C. RV and LV weights from both groups were measured for determination of the degree of hypertrophy. The vessel weights were also related to DNA content.
Molecular Biology and Immunohistochemical Procedures
GH-R Probe
The pT7T3 18 U plasmid contains a 560-bp BamHI fragment of the rat GH-R cDNA that encodes the early part of the extracellular domain of the GH-R and thus does not differentiate between the GH-R and GH binding protein. Antisense GH-R 35S-UTPlabeled RNA was synthesized according to the manufacturer's instructions (Promega).
IGF-I Probe
A 153-bp Sma I fragment of a genomic subclone of mouse IGF-I (exon 3 by analogy to human IGF-I) subcloned into a pSP64 plasmid was used as a template for probe synthesis.17 The plasmid was linearized with EcoRI and used as a template for synthesis of 35S-UTPlabeled IGF-I cRNA with SP6 RNA polymerase according to the manufacturer's instructions (Promega).
Hepatocyte Growth Factor Probe
To study the specificity of the induction of vascular gene expression, we determined the levels of hepatocyte growth factor. A 650-bp rat hepatocyte growth factor cDNA probe was labeled with 35S-UTP and synthesized with an in vitro transcription set according to the manufacturer's instructions (Promega) using a 1.4-kb EcoRI insert of pRBC1 in an Sac I plasmid linearized with BglII.
Solution Hybridization
Frozen tissue was homogenized and treated with proteinase K, and total nucleic acids were extracted with phenol/chloroform as previously described.29 A solution hybridization assay was used for quantification of IGF-I and GH-R mRNA.29 The probes were hybridized to total nucleic acid samples at 70°C for 24 hours. After RNase treatment, the precipitated protected hybrids were collected on glass-fiber filters (GF/C, Whatman International Ltd) and counted in a scintillation counter. The signal was compared with a standard curve based on known amounts of IGF-I or GH-R mRNA. The results were related to the DNA content in the total nucleic acid sample.30
RNase Protection
The specificity of the probes used in the solution hybridization assay was confirmed by separation of the protected fragments on a gel. Total RNA was prepared according to the modified method of Chomczynski and Sacchi.31 Samples of 25x10-6 to 35x10-6 g were hybridized in a buffer containing 22x10-3 mol/L Tris, 5x10-3 mol/L EDTA, 0.6 mol/L NaCl, 0.075x10-3 g/10-3 L tRNA, 0.75x10-3 mol/L dithiothreitol, 25% formamide, 0.1% (wt/vol) sodium dodecyl sulfate, and 500 000 cpm 35S-labeled probe and were incubated overnight at 70°C.
Single-stranded RNA was digested by addition of 300x10-6 L digestion buffer containing 10x10-3 mol/L Tris-HCl (pH 7.5), 300x10-3 mol/L NaCl, 5x10-3 mol/L EDTA, 40x10-6 g RNase A/10-3 L, and 2x10-6 g RNase T1/10-3 L in a 30-minute incubation at 37°C. After proteinase K digestion, the RNA was extracted with phenol/chloroform and precipitated with 2.5 vol ethanol using 10x10-6 g tRNA as carrier. The pellets were resuspended in loading buffer containing 80% formamide, 15% Ficoll, and 0.25% bromphenol blue. The protected fragments were separated by electrophoresis on 8x10-3 mol/L urea/6% polyacrylamide denaturing gel. As a molecular size marker, an end-labeled
174/HaeIII DNA marker (Promega) was prepared. The dried gel was exposed on a PhosphoImager screen (Molecular Dynamics Inc) for 3 to 7 days.
Immunohistochemistry
Three male Wistar-Kyoto rats underwent ACF surgery, and three sham-operated rats served as controls. Four days after surgery, the rats were euthanized and the caval vein was excised and embedded in OCT compound, rapidly frozen in 2-methylbutane chilled in liquid nitrogen, and stored at -80°C until further use.
Antiserum for rat IGF-Ib prohormone
The antiserum was raised against a 23amino acid synthetic peptide corresponding to a part of the rat IGF-Ib E-domain. The antiserum has been shown to specifically recognize IGF-Ib in immunoprecipitation experiments.32
IGF-Ib immunohistochemistry
Cryostat sections (6x10-6 m) were cut, adhered to microscope glasses, and air-dried followed by fixation in 4% paraformaldehyde in PBS, pH 7.4, for 15 minutes. The sections were blocked with 5% (wt/vol) dried fat-free milk in PBS and quickly rinsed, followed by incubation with the IGF-Ib antisera diluted 1:1000 in 0.5% (wt/vol) dried fat-free milk in PBS at 4°C overnight. The sections were rinsed three times in PBS and incubated for 1 hour at room temperature with anti-rabbit horseradish peroxidaseconjugated Fab fragments (Amersham) diluted 1:50 in 0.5% milk-PBS followed by three additional rinses and development in DAB-chromogen (1x10-3 g/10-3 L DAB and 0.02% H2O2). Two types of control experiments were used: (1) deletion of primary antibody and (2) incubations with unrelated nonimmune rabbit sera diluted 1:1000.
Statistical Analysis
Values are given as mean±SE. Statistical differences between groups were analyzed by one-way and two-way ANOVA followed by the Bonferroni post hoc test. With regard to time course effects, most changes have been assessed statistically considering the entire study period. A value of P<.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
|
|
IGF-I mRNA expression in the caval vein showed an eightfold increase at day 4 and a subsequent return to normal expression by day 12 (P<.05, Fig 2A, Table 2). No changes in aortic IGF-I mRNA expression were detected at any of the three time points (Fig 2B, Table 2). Caval vein GH-R mRNA expression was increased by approximately fourfold both 4 and 8 days after fistula induction. GH-R gene expression was normalized at day 12 (P<.05, Fig 3A, Table 2).
|
|
|
Renal Hypertensive Rats
Table 1 also shows data for the 2K1C groups. Systolic pressure increased progressively (P<.05) from days 2 (15%) and 4 (30%) up to day 7 (40%). The LV weight was increased (P<.05) already at day 2 (28%), day 4 (31%), and day 7 (42%), whereas RV weight showed no difference between 2K1C and sham rats. The RV/LV ratio decreased by some 19% over the 7-day experimental period (P<.05). Aortic wet weight showed a statistically significant difference between operated and sham groups during the study course (P<.05), whereas no difference was observed in caval vein wet weight between 2K1C and sham rats. Aortic and caval vein wet weights related to DNA content were similar in 2K1C and sham rats.
Aortic IGF-I mRNA was unchanged 2 days after renal clipping, whereas at 4 and 7 days after clipping, there was a 2.2-fold and 3.4-fold elevation of IGF-I gene expression, respectively (P<.05, Fig 2D). No induction above control level of IGF-I mRNA could be detected in the caval vein (Fig 2C, Table 2). There was a fivefold increase in aortic GH-R mRNA 7 days after induction of renal hypertension versus sham operation (P<.05, Fig 3B, Table 2). No change was found at the two earlier time points.
Immunohistochemistry
IGF-Ib immunoreactivity was demonstrated in the caval vein of ACF and sham rats (Fig 4a and 4b). In the caval vessel wall of the ACF rats, IGF-Ib appeared to be increased in cells of the media, possibly in smooth muscle cells, and also in cells in the adventitia. In sections incubated with control nonimmune rabbit serum, only faint background staining was seen (Fig 4c). No staining was observed when the primary antibody was omitted (data not shown).
|
Unrelated Gene
The caval vein and aorta in the two intervention groups did not show any statistically significant difference over time in hepatocyte growth factor levels, and values were similar to those of the sham group (data not shown).
RNase Protection
RNase-protected probe fragments were analyzed on denaturing polyacrylamide gels. For IGF-I (Fig 5, top), the undigested probe was found to be approximately 170 bases long, consisting of a 153-base insert and additional polylinker bases (lane 1). One hundred and twenty bases were protected when the probe was hybridized to RNA from aorta, caval vein, and liver (lanes 6, 7, and 8, respectively), with the smaller size probably reflecting a certain mismatch between mouse probe and rat RNA. A background transcript of approximately 125 bases was also protected (lanes 2 through 8). This mismatch in protected fragments on the gel could be reflected in the results of the solution hybridization assay but would probably cause equally high background values in both the experimental and sham groups. Moreover, for the GH-R (Fig 5, bottom), the undigested probe was found to be 560 bases long, corresponding to the insert (lane 1). Four hundred and ten bases were RNase-protected when the probe was hybridized to RNA from aorta, caval vein, and liver (lanes 6, 7, and 8, respectively). The smaller size of protected fragment reflects the fact that the first part of the probe is not homologous to the rat GH-R mRNA.19
|
| Discussion |
|---|
|
|
|---|
The relationship between hemodynamic stimulation and growth factor gene expression is important when one is comparing the magnitude and rate of onset of a circulatory challenge. However, both the caval vein and aorta show different features regarding structure and function. Thus, when a fistula is created between the abdominal aorta and caval vein, the latter will be immediately exposed to an increase in volume flow and right atrial pressure.33 34 35 36 Surprisingly, radiotelemetry for blood pressure recordings showed no changes in central venous pressure but an immediate and prompt fall in mean arterial pressure and an increase in heart rate after induction of the fistula (Fig 1). This is an intriguing finding, because it means that the venous circulation has the capacity to accommodate rapidly, and to a substantial degree, a large increase in volume flow without increasing pressure. Hence, capacitance vessels must be markedly distended. Moreover, using the ultrasound/Doppler technique,37 we showed a 2.4-fold increase in RV cardiac output 7 days after fistula surgery versus sham rats (280±5 versus 118±2x10-3 L/min, P<.05, unpublished results). Taken together, these observations suggest that the prompt and immediate increase in volume flow to the venous circulation, without any changes in central venous pressure, causes a marked increase in vascular wall stress, hence rapidly stimulating the GH/IGF-I axis locally in the vascular wall.
In 2K1C renal hypertension, in which the aorta is exposed to a more gradual increase in systolic wall stress, a more moderate and late increase in IGF-I mRNA levels occurred. Comparing this finding with that which is observed in the caval vein of ACF rats, it seems reasonable to assume that aortic IGF-I synthesis also depends on an elevation in blood pressure and wall stress. It would then seem that the differences between these experimental models in time course and magnitude, with regard to gene induction, are possibly a consequence of both a relatively smaller increase in aortic wall stress in the 2K1C groups and the large and prompt increase in the caval vein wall stress in the ACF groups.
The lack of overexpression of IGF-I and GH-R mRNAs in the aorta of the ACF groups and in the caval vein of the 2K1C groups was probably due to the unchanged (2K1C) or even reduced (ACF) systolic wall stress. This is in agreement with earlier findings in hearts14 15 in which IGF-I and GH-R gene expression was not increased despite a substantial increase in diastolic wall stress in the left ventricle of ACF animals as well as in the unchallenged right ventricle of 2K1C rats. It should be noted that the left ventricle in ACF animals demonstrates hypertrophy to a similar extent as the right ventricle, indicating that IGF-I is not the only important factor for generating a hypertrophic response, at least in the heart. One can speculate that the elevated diastolic wall stress in the left ventricle of ACF animals is of importance for promoting growth and may trigger the expression of other growth factors.38 In agreement with the present study, Calderone and coworkers39 have shown that various forms of hemodynamic overload are associated with different molecular phenotypes and patterns of peptide growth factor induction.
In the present study, both the ACF caval vein and 2K1C aorta showed evidence for adaptive growth during the first 4 days after surgery. The caval vein in the ACF group showed a fourfold increase in wet weight per DNA content at day 4 compared with the respective sham groups. In contrast, the aorta in the 2K1C groups showed no change in wet weight per DNA content versus sham, whereas aortic wet weight in the 2K1C groups showed a small but significant increase in wet weight. Taken together, the present results show both gene induction and evidence for structural growth, but they do not shed light on the precise nature of the growth response, eg, hypertrophy, hyperplasia, or polyploidy, although the ACF caval vein showed evidence for hypertrophy. Furthermore, it is reasonable to assume that the peak growth response may vary during the first week after induction of pressure and volume load,14 15 depending on the intensity of the hemodynamic stimulus, the biological variance, and the prevailing structure of the vascular wall. However, we cannot rule out the possibility that aortic and caval vein tissues have different, inherent responsiveness when exposed to hemodynamic loading. Accordingly, such a situation could yield a different pattern of gene expression of the components in the GH/IGF-I axis in the two vessel types.
GH and thyroxine have previously been demonstrated to be involved in the development of LV hypertrophy and structural adaptation of the skeletal muscle vascular bed in renal hypertensive, hypophysectomized rats.40 In the present study, we have demonstrated that the overexpression of GH-R mRNA occurred in parallel with or shortly after the peak of IGF-I mRNA. The reason for the elevated GH-R expression is not clear, although it may indicate that the IGF-I gene expression response, as well as the subsequent protein synthesis, is not enough to create a sufficient adaptive hypertrophy. Supportive evidence for this notion was presented in a recent study by Isgaard and coworkers,15 who found increased levels of both IGF-I and GH-R mRNA in the heart, with a temporal relationship between these factors in response to volume overload.
Circulating neurohormonal factors such as Ang II and norepinephrine are elevated early in both models used in the present report. These factors are important contributors in creating an optimal milieu to facilitate the adaptational growth response in the tissue. However, circulating levels of Ang II are not likely to solely regulate the IGF-I tissue levels, because both types of vessels in the two experimental models are exposed to similar concentrations of circulating Ang II, which would result in a general overexpression of IGF-I mRNA. Several studies have documented increased local activity of the components of the renin-angiotensin system, such as an increased aortic angiotensin-converting enzyme mRNA by Northern blot analyses in renal hypertension41 as well as increased angiotensin-converting enzyme activity in the pressure-overloaded left ventricle.42 Thus, increased autocrine/paracrine activation of Ang II may be involved in causing vascular hypertrophy directly, either dependently or independently of systemic factors and hemodynamic stimuli.
In the present study, we have characterized the extent and time course of the GH/IGF-I axis response in the caval vein and aorta in two different hemodynamic modelsone with a rapid and the other with a slower onset of pressure and volume loads. Taken together, our findings indicate that increased systolic wall stress may be one factor, possibly acting in concert with neurohormonal activation, that augments gene expression of both GH-R and IGF-I mRNAs and IGF-I protein contents in the vessel wall. These factors are associated with the alteration in vascular structure in the vessel wall. The early and more pronounced increase of the GH/IGF-I axis in the caval vein of the ACF groups may suggest that the magnitude of wall stress correlates with the growth response.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
| Footnotes |
|---|
Received May 17, 1996;
first decision June 27, 1996; first decision August 5, 1996;
| References |
|---|
|
|
|---|
2. Agrotis A, Bray PJ, Saltis J, Bobik A. Vascular smooth muscle cell proliferation in SHR and WKY rats: evidence for specific differences in growth inhibitory regulatory mechanisms. Clin Exp Pharmacol Physiol. 1993;20:327-330.[Medline] [Order article via Infotrieve]
3. Holycross BJ, Peach MJ, Owens GK. Angiotensin II stimulates increased protein synthesis, not increased DNA synthesis, in intact rat aortic segments, in vitro. J Vasc Res. 1993;30:80-86.[Medline] [Order article via Infotrieve]
4. Owens GK, Schwartz SM. Alterations in vascular smooth muscle mass in the spontaneously hypertensive rat: role of cellular hypertrophy, hyperploidy, and hyperplasia. Circ Res. 1982;51:280-289.
5. Anversa P, Capasso JM. Cardiac hypertrophy and ventricular remodeling. Lab Invest. 1991;64:441-445.[Medline] [Order article via Infotrieve]
6. Owens GK, Reidy MA. Hyperplastic growth response of vascular smooth muscle cells following induction of acute hypertension in rats by aortic coarctation. Circ Res. 1985;57:695-705.
7. Owens GK, Schwartz SM. Vascular smooth muscle cell hypertrophy and hyperploidy in the Goldblatt hypertensive rat. Circ Res. 1983;53:491-501.
8. Dzau VJ, Gibbons GH, Morishita R, Pratt RE. New perspectives in hypertension research: potentials of vascular biology. Hypertension. 1994;23(part 2):1132-1140.
9. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
10. Hayzer DJ, Cicila G, Cockerham C, Griendling KK, Delafontaine P, Ng S, Runge MS. Endothelin A and B receptors are down-regulated in the hearts of hypertensive rats. Am J Med Sci. 1994;307:222-227.[Medline] [Order article via Infotrieve]
11. Cooper G, Kent RL, Uboh CE, Thompson EW, Marino TA. Hemodynamic versus adrenergic control of cat right ventricular hypertrophy. J Clin Invest. 1985;75:1403-1414.[Medline] [Order article via Infotrieve]
12. Lever AF, Harrap SB. Essential hypertension: a disorder of growth with origins in childhood? J Hypertens. 1992;10:101-120.[Medline] [Order article via Infotrieve]
13. Donohue TJ, Dworkin LD, Lango MN, Fliegner K, Lango RP, Benstein JA, Slater WR, Catanese VM. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation. 1994;89:799-809.
14. Wåhlander H, Isgaard J, Jennische E, Friberg P. Left ventricular insulin-like growth factor I increases in early renal hypertension. Hypertension. 1992;19:25-32.
15. Isgaard J, Wåhlander H, Adams MA, Friberg P. Increased expression of growth hormone receptor mRNA and insulin-like growth factor I mRNA in volume-overloaded hearts. Hypertension. 1994;23(part 2):884-888.
16. D'Ercole JA, Stiles AD, Underwood LE. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci U S A. 1984;81:935-939.
17. Mathews LS, Norstedt G, Palmiter RD. Regulation of insulin-like growth factor I gene expression by growth hormone. Proc Natl Acad Sci U S A. 1986;83:9343-9347.
18. Isgaard J, Nilsson A, Vikman K, Isaksson OGP. Growth hormone regulates the level of insulin-like growth factor-I mRNA in rat skeletal muscle. J Endocrinol. 1989;120:107-112.
19. Mathews LS, Engberg B, Norstedt G. Regulation of rat growth hormone receptor gene expression. J Biol Chem. 1989;264:9905-9910.
20. Nilsson A, Carlsson B, Mathews LS, Isaksson OPG. Growth hormone regulation of the growth hormone receptor mRNA in cultured rat epiphyseal chondrocytes. Mol Cell Endocrinol. 1990;70:237-246.[Medline] [Order article via Infotrieve]
21. Billestrup N, Möldrup A, Serup P, Mathews LS, Norstedt G, Nielsen JH. Introduction of exogenous growth hormone receptors augments growth hormone-responsive insulin biosynthesis in rat insulinoma cells. Proc Natl Acad Sci U S A. 1990;87:7210-7214.
22. Fath KA, Alexander WR, Delafontaine P. Abdominal coarctation increases insulin-like growth factor I mRNA levels in rat aorta. Circ Res. 1993;72:271-277.
23. Russell-Jones DL, Leach RM, Ward JPT, Thomas CR. Insulin-like growth factor-I gene expression is increased in the right ventricular hypertrophy induced by chronic hypoxia in the rat. J Mol Endocrinol. 1993;10:99-102.
24. Delafontaine P, Lou H, Alexander WR. Regulation of insulin-like growth factor I messenger RNA levels in vascular smooth muscle cells. Hypertension. 1991;18:742-747.
25. Chen Y, Bornfeldt KE, Arner A, Jennische E, Malmquist U, Uvelius B, Arnquist HJ. Increased insulin-like growth factor I in hypertrophying smooth muscle. Am J Physiol. 1994;266:E224-E229.[Medline] [Order article via Infotrieve]
26. Dobrin PB. Mechanical factors associated with the development of intimal and medial thickening in vein grafts subjected to arterial pressure: a model of arteries exposed to hypertension. Hypertension. 1995;26:38-43.
27. Lundgren Y, Hallbäck M, Wiess L, Folkow B. Rate and extent of adaptive cardiovascular changes in rats during experimental renal hypertension. Acta Physiol Scand. 1974;91:103-115.[Medline] [Order article via Infotrieve]
28. Garcia R, Diebold S. Simple, rapid, and effective method of producing aortocaval shunts in the rats. Cardiovasc Res. 1990;24:430-432.
29. Durnam DM, Palmiter RD. A practical approach for quantitating specific mRNAs by solution hybridization. Anal Biochem. 1983;131:385-393.[Medline] [Order article via Infotrieve]
30. Labarca C, Paigen KA. Simple, rapid and sensitive DNA assay procedure. Anal Biochem. 1980;102:344-352.[Medline] [Order article via Infotrieve]
31. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.[Medline] [Order article via Infotrieve]
32. Bach MA, Roberts CTJ, Smith EP, LeRoith D. Alternative splicing produces messenger RNAs encoding insulin-like growth factor-I prohormones that are differentially glycosylated in vitro. Mol Endocrinol. 1990;4:899-904.
33. Ruzicka M, Yuan B, Harmsen E, Leenen FHH. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats: effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker. Circulation. 1993;87:921-930.
34. Liu Z, Hilbelink DR, Crockett WB, Gerdes MA. Regional changes in hemodynamics and cardiac myocyte size in rats with aortacaval fistulas, 1: developing and established hypertrophy. Circ Res. 1991;69:52-58.
35. Ruzicka M, Leenen FHH. Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. Circulation. 1995;91:16-19.
36. Oka T, Nishimura H, Ueyama M, Kubota J, Kuwamura K. Haemodynamic and neurohumoral changes in spontaneously hypertensive rats with aortacaval fistulae. Clin Sci. 1993;84:531-535.[Medline] [Order article via Infotrieve]
37. Cittadini A, Strömer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS. Differential cardiac effects of growth hormone and insulin-like growth factor-I in the rat: a combined in vivo and in vitro evaluation. Circulation. 1996;93:800-809.
38. Boer PH, Ruzicka M, Lear W, Harmsen E, Rosenthal J, Leenen FH. Stretch-mediated activation of cardiac renin gene. Am J Physiol. 1994;267:H1630-H1636.[Medline] [Order article via Infotrieve]
39. Calderone A, Takahashi N, Izzo NJ Jr, Thaik CM, Colucci WS. Pressure- and volume-induced left ventricular hypertrophies are associated with distinct myocyte phenotypes and differential induction of peptide growth factors mRNAs. Circulation. 1995;92:2385-2390.
40. Folkow B, Isaksson OGP, Karlström G, Lever AF, Nordlander M. Trophic effects of hypophyseal hormones on resistance vessels and the heart in normotensive and renal hypertensive rats. Acta Physiol Scand. 1992;144:291-306.[Medline] [Order article via Infotrieve]
41. Shiota N, Miyazaki M, Okunishi H. Increase of angiotensin converting enzyme gene expression in the hypertensive aorta. Hypertension. 1992;20:168-174.
42. Schunkert H, Jackson B, Tang SS, Schoen FJ, Smits JFM, Apstein CS, Lorell BH. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation. 1993;87:1328-1339.
This article has been cited by other articles:
![]() |
C. Ohlsson, S. Mohan, K. Sjogren, A. Tivesten, J. Isgaard, O. Isaksson, J.-O. Jansson, and J. Svensson The Role of Liver-Derived Insulin-Like Growth Factor-I Endocr. Rev., August 1, 2009; 30(5): 494 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. R. Schwarz, P. Jammula, R. Gupta, and S. Rosanio A Case and Review of Acromegaly-Induced Cardiomyopathy and the Relationship Between Growth Hormone and Heart Failure: Cause or Cure or Neither or Both? Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2006; 11(4): 232 - 244. [Abstract] [PDF] |
||||
![]() |
P. Delafontaine, Y.-H. Song, and Y. Li Expression, Regulation, and Function of IGF-1, IGF-1R, and IGF-1 Binding Proteins in Blood Vessels Arterioscler Thromb Vasc Biol, March 1, 2004; 24(3): 435 - 444. [Abstract] [Full Text] |
||||
![]() |
A.F.C. Schut, J.A.M.J.L. Janssen, J. Deinum, J.M. Vergeer, A. Hofman, S.W.J. Lamberts, B.A. Oostra, H.A.P. Pols, J.C.M. Witteman, and C.M. van Duijn Polymorphism in the Promoter Region of the Insulin-like Growth Factor I Gene Is Related to Carotid Intima-Media Thickness and Aortic Pulse Wave Velocity in Subjects With Hypertension Stroke, July 1, 2003; 34(7): 1623 - 1627. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ren, L. Jefferson, J. R. Sowers, and R. A. Brown Influence of Age on Contractile Response to Insulin-Like Growth Factor 1 in Ventricular Myocytes From Spontaneously Hypertensive Rats Hypertension, December 1, 1999; 34(6): 1215 - 1222. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |